Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
KALA
KALA BIO, INC.
NASDAQ
$0.29
▼ DOWN 0.91% (-0.00)

KEY STATISTICS

Market Cap$5.75 M
52w High$95.50
52w Low$0.29
Dividend Yield—
Frequency—
P/E-0.10
Volume263.64K
Shares Out.19.34M

COMPANY

LEADERSHIP

Avi Minkowitz
CHIEF EXECUTIVE
Avi Minkowitz

COMPENSATION 2026

Salary$111,866
Stock Awards$166,413
Incentive Plan Pay$0
All Other Comp.$896
Total$906,642

ABOUT

SECTOR
Healthcare
WENT PUBLIC
July 20, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
6

PRICE TARGET

Target High$35.00
Target Low$1.50
Target Median$18.25
Target Consensus$18.25

UPCOMING EARNINGS

DateNov 10, 2026
DayTuesday
Rev. Est.—
NOV
10
TUE

SPLIT RECORD

DATETYPERATIO
2026-05-11Reverse1:50
2022-10-21Reverse1:50
2022-08-26Forward2:1

ETFS HOLDING THIS STOCK

ETFS HOLDING
1
LISTED HERE
1
RANKED BY POSITION SIZE
VXF
0.00%
220.6K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
19.67%
HOLDERS
52
TOP 8 OF 52 · RANKED BY POSITION SIZE
Baker Bros. Advisors LP
1.8M sh
$1M
Renaissance Technologies LLC
417.5K sh
$72.27K
Pictet Asset Management Ltd
392.1K sh
$2.08M
Citadel Advisors LLC
281.6K sh
$48.75K
Geode Capital Management, LLC
261.1K sh
$45.19K
Woodline Partners LP
247.5K sh
$378.62K
Vanguard Group Inc
210.8K sh
$322.56K
Teachers Advisors, LLC
189.8K sh
$1.57M

PRICE

$0.29 ▼ DOWN 0.91% (−$0.00)
OVERLAYS
$0.29$0.29$0.309:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM0.29

About KALA BIO, Inc.

https://www.kalarx.com ↗

Kala Bio, founded in 2009 in Arlington, MA, develops biopharmaceuticals using proprietary mucus-penetrating nanoparticles, initially targeting ophthalmic diseases. Co-founders include Justin Hanes, Robert S. Langer, and Colin R. Gardner.

INDUSTRY

Biotechnology

A PRODUCT KALA BIO, INC. IS KNOWN FOR

KPI-012
KPI-012

KPI-012, a cell-free therapy from mesenchymal stem cell secretomes, targets severe ocular diseases like PCED. It is KALA BIO's lead candidate, reflecting their shift after selling previous assets.

COMPETITORS

COMPETITOR
ALC COMPARE
ALDX COMPARE
BLCO COMPARE
KRYS COMPARE
TARS COMPARE

KALA BIO in 2025

SENTIMENT: − NEGATIVE
Kim Brazzell
REGULATORY · SEPTEMBER 29, 2025

KALA BIO's Lead Product Candidate Fails Pivotal Phase 2b Clinical Trial, Halting Development and Triggering Strategic Overhaul

On September 29, 2025, KALA BIO, Inc. announced that its CHASE Phase 2b clinical trial for KPI-012, a treatment for persistent corneal epithelial defect (PCED), failed to meet its primary and key secondary endpoints. This critical setback led the company to cease all development of KPI-012 and its underlying mesenchymal stem cell secretome platform, prompting a significant workforce reduction and a re-evaluation of all strategic options.

LEADERSHIP STRATEGY · DECEMBER 2025 · IN PROGRESS

KALA BIO Appoints New CEO and Secures $6 Million Investment Following Clinical Trial Setback and Restructuring

Following the failure of its Phase 2b CHASE clinical trial for KPI-012 in September 2025, KALA BIO, Inc. underwent a significant strategic overhaul. This included ceasing the development of KPI-012, restructuring its workforce with a 51% reduction, and appointing investor David E. Lazar as the new CEO and Chairman of the Board, who is leading a strategic re-evaluation of the company's assets and future direction.

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow5
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book5
Overall Score2

SECTORS PEERS

PEERPRICE
XTLB$1.99COMPARE
KTTA$0.45COMPARE
ENSC$0.41COMPARE
SNGX$0.35COMPARE

INSIDER TRADES

★
DIRECTOR:
Berger Chaim D.
— · —
2026-01-30
★
DIRECTOR:
Colman Yonatan C.
— · —
2026-01-30
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Minkowitz Avraham
— · —
2026-01-30
★
DIRECTOR:
Posen Hillel D.
— · —
2026-01-30